Full-Time

Senior Engineer I

Automation, Technical Development, Int

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Senior

Norwood, MA, USA

Position is based in Moderna’s Norwood, MA offices.

Category
Robotics and Automation Engineering
Mechanical Engineering
Requirements
  • Bachelor’s degree in engineering or related field or relevant experience; a combination of education and experience may be considered.
  • 8 - 10 years of experience working in combination of manufacturing and lab systems in Pharmaceutical/Biotechnology
  • Experience with translating requirements against ISA95 ISA88 structure from I/O (PLC, HMI, lab instruments) to DCS (DeltaV or related) then MES (Syncade or related).
  • Strong automation background in DeltaV Control System including both continuous and batch processes. Well verse in S88 batch recipe creation, implementation, and troubleshooting.
  • Well verse working with BUS technologies including Fieldbus, HART, Ethernet I/P, OPC and classic IO. Knowledgeable in using middleware technologies like Kepware, OPC tools.
  • Experience in tech transfer processes between MST, Process Development, Technical Development and Manufacturing.
  • Experience with IQ/OQ/PQ validation process for digital manufacturing/lab systems and with computerized system validation activities according to 21 CFR Part 11, Annex 11 and other regulatory requirements.
Responsibilities
  • Collaborate with digital manufacturing and QC teams to develop an effective and efficient digital process around automation and integration of both manufacturing and lab equipment to various digital systems.
  • Partner with automation engineers, scientists, lab engineers, and operations teams to effectively support and influence the design and deployment of a robust production of Individualized Neoantigen Therapies.
  • Collaborate with key stakeholders such as Technical and Analytical development, manufacturing, quality, and automation.
  • Apply an operational excellence mindset to help identify, devise, and recommend new opportunities to optimize current processes.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

54%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?